Celularity
CELU
33 hedge funds and large institutions have $2.9M invested in Celularity in 2026 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.27% less ownership
Funds ownership: 7.69% → 7.42% (-0.27%)
2% less capital inflows, than outflows
Capital inflows: $199K | Capital outflows: $203K
18% less funds holding
Funds holding: 40 → 33 (-7)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$79.5K |
| 2 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$42.2K |
| 3 |
Sky Investment Group
Hartford,
Connecticut
|
+$30.3K |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$25.7K |
| 5 |
Mercer Global Advisors
Denver,
Colorado
|
+$15.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$100K |
| 2 |
HRT Financial
New York
|
-$33K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$18.2K |
| 4 |
CenterStar Asset Management
Chicago,
Illinois
|
-$12.9K |
| 5 |
Jane Street
New York
|
-$11.5K |
CELU Hedge Fund Activity: Q3 2026 in Review
33 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Celularity (CELU) for Q3 2026, worth a combined $2.9M — up 18% from $2.46M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CELU and 3 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was UBS Group, adding an estimated $79.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $100K sold.
- 33 institutional investors held Celularity (CELU) as of Q3 2026, down from 40 in Q2 2026.
- Funds reported $2.9M of Celularity stock for Q3 2026, up 18% quarter-over-quarter.
- 3 funds opened new Celularity positions in Q3 2026 and 9 closed out, a net change of -6 holders.
- The largest Celularity buyer in Q3 2026 was UBS Group, an estimated $79.5K added.
- The largest Celularity seller in Q3 2026 was Citadel Advisors, an estimated $100K sold.
Based on aggregated 13F filings for Q3 2026.